There has been longstanding interest in identifying treatment strategies for patients with TSC diagnosed at early ages where the potential effects of mTOR inhibitors or other therapies could drastically improve or even prevent the development of several TSC manifestations, including seizures, developmental delay, autism, renal disease, cutaneous tumors, and other lesions, by initiating treatment with mTOR inhibitors early in life. Here, MTOR is linked to kidney disorder.